A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status.
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 15 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.